Trail/trail receptor expression on T-cell subtypes in patients with myasthenia gravis

Ali Dincer; Dilek İşcan; Atıl Bişgin; Filiz Koç

Makale detayları

Trail/trail receptor expression on T-cell subtypes in patients with myasthenia gravis

Yazarlar:

Ali Dincer | Dilek İşcan | Atıl Bişgin | Filiz Koç

Yayıncı:

Ondokuz Mayıs University

Ana Başlıklar:

Neurology and Neuromuscular Diseases

Dergi:

Deneysel ve Klinik Tıp Dergisi Vol.42 Issue 3, pp.257-265

Belge Tipi:

Makale

Yayın Tarihi:

9/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001359815

pISSN:

1309-4483

Anahtar kelimeler:

Özet:

 Anti- acetylcholine receptor Anti-AChR is the most commonly seen and well known antibody among Myasthenia Gravis MG related antibodies and it is produced by B lymphocytes; however,,T-lymphocytes also contribute to the development of the autoimmune response. Apoptosis, programmed cell death, regulates the activities of central and peripheral T cells during immune response. In this regard, the goal of this study was to determine T cell related TNF-related apoptosis-inducing ligand TRAIL receptor and ligand composition; and TRAILs role in the development and progression of the disease in MG patients. Thus, we aimed to understand how TRAIL and its receptors affect T cell function in the pathophysiological mechanism of MG. This study included a total of 25 patients 13 females and 12 males, who were admitted to the department of neurology and diagnosed with MG according to clinical, electrophysiological and laboratory data, and 16 age- and sex-matched healthy volunteers. The expression profile of TRAIL and its receptors on CD3 CD4 and CD3 CD8 T lymphocytes were investigated with flow cytometry in peripheral blood samples. Furthermore, the relationship between TRAILTRAIL receptor expression and clinical findings and , treatment protocol of the patients were analyzed with Spearmans Rho. It was detected that TRAILTRAIL receptor expression on both CD4 and CD8 T cells were significantly higher in MG patients compared to control group. In MG patients, while death receptor-4 DR4 and decoy receptors DcR, DcR1 and DcR2, were correlated with CD8 T cells, they were not correlated with CD4 T cells. In this study, which evaluated TRAILTRAIL receptor expression on T cell subtypes in MG patients, we showed that TNF and TRAILTRAIL receptor system play a significant role in MG and concluded that these data will contribute to the development of new gene therapies.

 Anti- acetylcholine receptor Anti-AChR is the most commonly seen and well known antibody among Myasthenia Gravis MG related antibodies and it is produced by B lymphocytes; however,,T-lymphocytes also contribute to the development of the autoimmune response. Apoptosis, programmed cell death, regulates the activities of central and peripheral T cells during immune response. In this regard, the goal of this study was to determine T cell related TNF-related apoptosis-inducing ligand TRAIL receptor and ligand composition; and TRAILs role in the development and progression of the disease in MG patients. Thus, we aimed to understand how TRAIL and its receptors affect T cell function in the pathophysiological mechanism of MG. This study included a total of 25 patients 13 females and 12 males, who were admitted to the department of neurology and diagnosed with MG according to clinical, electrophysiological and laboratory data, and 16 age- and sex-matched healthy volunteers. The expression profile of TRAIL and its receptors on CD3 CD4 and CD3 CD8 T lymphocytes were investigated with flow cytometry in peripheral blood samples. Furthermore, the relationship between TRAILTRAIL receptor expression and clinical findings and , treatment protocol of the patients were analyzed with Spearmans Rho. It was detected that TRAILTRAIL receptor expression on both CD4 and CD8 T cells were significantly higher in MG patients compared to control group. In MG patients, while death receptor-4 DR4 and decoy receptors DcR, DcR1 and DcR2, were correlated with CD8 T cells, they were not correlated with CD4 T cells. In this study, which evaluated TRAILTRAIL receptor expression on T cell subtypes in MG patients, we showed that TNF and TRAILTRAIL receptor system play a significant role in MG and concluded that these data will contribute to the development of new gene therapies.

 Anti- acetylcholine receptor Anti-AChR is the most commonly seen and well known antibody among Myasthenia Gravis MG related antibodies and it is produced by B lymphocytes; however,,T-lymphocytes also contribute to the development of the autoimmune response. Apoptosis, programmed cell death, regulates the activities of central and peripheral T cells during immune response. In this regard, the goal of this study was to determine T cell related TNF-related apoptosis-inducing ligand TRAIL receptor and ligand composition; and TRAILs role in the development and progression of the disease in MG patients. Thus, we aimed to understand how TRAIL and its receptors affect T cell function in the pathophysiological mechanism of MG. This study included a total of 25 patients 13 females and 12 males, who were admitted to the department of neurology and diagnosed with MG according to clinical, electrophysiological and laboratory data, and 16 age- and sex-matched healthy volunteers. The expression profile of TRAIL and its receptors on CD3 CD4 and CD3 CD8 T lymphocytes were investigated with flow cytometry in peripheral blood samples. Furthermore, the relationship between TRAILTRAIL receptor expression and clinical findings and , treatment protocol of the patients were analyzed with Spearmans Rho. It was detected that TRAILTRAIL receptor expression on both CD4 and CD8 T cells were significantly higher in MG patients compared to control group. In MG patients, while death receptor-4 DR4 and decoy receptors DcR, DcR1 and DcR2, were correlated with CD8 T cells, they were not correlated with CD4 T cells. In this study, which evaluated TRAILTRAIL receptor expression on T cell subtypes in MG patients, we showed that TNF and TRAILTRAIL receptor system play a significant role in MG and concluded that these data will contribute to the development of new gene therapies.

 Anti- acetylcholine receptor Anti-AChR is the most commonly seen and well known antibody among Myasthenia Gravis MG related antibodies and it is produced by B lymphocytes; however,,T-lymphocytes also contribute to the development of the autoimmune response. Apoptosis, programmed cell death, regulates the activities of central and peripheral T cells during immune response. In this regard, the goal of this study was to determine T cell related TNF-related apoptosis-inducing ligand TRAIL receptor and ligand composition; and TRAILs role in the development and progression of the disease in MG patients. Thus, we aimed to understand how TRAIL and its receptors affect T cell function in the pathophysiological mechanism of MG. This study included a total of 25 patients 13 females and 12 males, who were admitted to the department of neurology and diagnosed with MG according to clinical, electrophysiological and laboratory data, and 16 age- and sex-matched healthy volunteers. The expression profile of TRAIL and its receptors on CD3 CD4 and CD3 CD8 T lymphocytes were investigated with flow cytometry in peripheral blood samples. Furthermore, the relationship between TRAILTRAIL receptor expression and clinical findings and , treatment protocol of the patients were analyzed with Spearmans Rho. It was detected that TRAILTRAIL receptor expression on both CD4 and CD8 T cells were significantly higher in MG patients compared to control group. In MG patients, while death receptor-4 DR4 and decoy receptors DcR, DcR1 and DcR2, were correlated with CD8 T cells, they were not correlated with CD4 T cells. In this study, which evaluated TRAILTRAIL receptor expression on T cell subtypes in MG patients, we showed that TNF and TRAILTRAIL receptor system play a significant role in MG and concluded that these data will contribute to the development of new gene therapies.

Makale detayları

Trail/trail receptor expression on T-cell subtypes in patients with myasthenia gravis

Yazarlar:

Ali Dincer | Dilek İşcan | Atıl Bişgin | Filiz Koç

Yayıncı:

Ondokuz Mayıs University

Ana Başlıklar:

Neurology and Neuromuscular Diseases

Dergi:

Deneysel ve Klinik Tıp Dergisi Vol.42 Issue 3, pp.257-265

Belge Tipi:

Makale

Yayın Tarihi:

9/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001359815

pISSN:

1309-4483

Myasthenia Gravis

thymus

TRAIL

apoptosis

CD4+

CD8+

Sayı

Makale detayları

Trail/trail receptor expression on T-cell subtypes in patients with myasthenia gravis

Yazarlar: Ali Dincer | Dilek İşcan | Atıl Bişgin | Filiz Koç

Yayıncı: Ondokuz Mayıs University

Ana Başlıklar: Neurology and Neuromuscular Diseases

Dergi: Deneysel ve Klinik Tıp Dergisi Vol.42 Issue 3, pp.257-265

Belge Tipi: Makale

Yayın Tarihi: 9/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001359815

pISSN: 1309-4483

Myasthenia Gravis

thymus

TRAIL

apoptosis

CD4+

CD8+

Sayı

Yazarlar:

Ali Dincer | Dilek İşcan | Atıl Bişgin | Filiz Koç

Yayıncı:

Ondokuz Mayıs University

Ana Başlıklar:

Neurology and Neuromuscular Diseases

Dergi:

Deneysel ve Klinik Tıp Dergisi Vol.42 Issue 3, pp.257-265

Belge Tipi:

Makale

Yayın Tarihi:

9/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001359815

pISSN:

1309-4483